Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Conclusions
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
81
libvatrep - TRPV1 antagonist
Indication
Phase
NCT04630158 SAHARA (CSAF312B12201)
Chronic ocular surface pain
Phase 2
Patients
150
Primary
Change in mean pain severity Visual Analog Scale
Outcome
Measures
Arms
Intervention
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
Target
Patients
Placebo Comparator: SAF312 Placebo. Randomized to a 1:1:1 topical eye
drops, twice daily
Experimental: SAF312 dose 1. Randomized to a 1:1:1 topical eye drops,
twice daily
Experimental: SAF312 dose 2. Randomized to a 1:1:1 topical eye drops,
twice daily
Subjects with CICP persisting at least for 4 months after refractive surgery and
chronicity confirmed during the observational period.
Readout
Milestone(s)
2023
Publication
2023
Investor Relations | Q2 2023 Results
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation